Study of Ceftriaxone In ALS Seeks Participants

A multicenter study of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis (ALS) remains open.

Ceftriaxone is an antibiotic that may improve the clearance of glutamate, a potentially toxic nervous system chemical, from the area around motor neurons, the cells that are destroyed in ALS.

Participants must meet study requirements, including adequate respiratory function and willingness to have a central venous catheter placed in a vein above the heart, through which the study medication or a placebo will be given.

For details, see Ceftriaxone: Trial in Subjects With ALS.